1Benson MC，Ring KS，Olsson C A．Thedeterm ination of stage D－O carcinoma of the pr ostate using PSA density[M]．September：Urologist′s Correspondence club，1989，24
3WANG M C, PAPSIDERO L D, KURIYAMA M, et al. Prostate antigen: A new potential marker for prostatic cancer[J]. Prostate, 1981, 2 : 89-96.
4CHRISTENSSON A, LAURELL C B, LILJA H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine protease inhibitors [J]. Eur J Biochem, 1990, 194: 755-763.
5LEINONEN J, ZHANG W M, STENMAN U H. Complex formation between PSA isoenzymes and protease inhibitors[J]. J Urol, 1996, 155: 1 099-1 103.
6LILJA H, CHRISTENSSON A, DAHLEN U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin[J]. Clin Chem, 1991, 37: 1 618-1 625.
7BABAIAN R J, FRITSCHE H A, EVANS R B.Prostate-specific antigen and prostate gland volume: Correlation and clinical application[J]. J Clin Lab Anal, 1990, 4: 135-137.
8ARMBUSTER D A. Prostate-specific antigen: Biochemistry, analytical methods,and clinical applieation[J]. Clin Chem, 1993, 39: 181-195.
9HETHERINGTON J W, SIDDALL J K, COOPER E H. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer [J]. Eur Urol, 1988, 14: 1-5.
10CATALONA W J, SMITH D S, WOLFERT R L, et al. Evaluation of percentage of free serum prostatespeeifie antigen to improve specificity of prostate cancer screening[J]. JAMA, 1995, 274:1 214-1 220.
